Cite
HARVARD Citation
Chaurasia, P. et al. (n.d.). Rigosertib in Combination with Azacitidine Modulates Epigenetic Pathways and can Overcome Clinical Resistance to Hypomethylating Agents in Myelodysplastic Syndromes (MDS). Leukemia research. pp. S121-. [Online].